Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension Study of Guadecitabine in Subjects from Prior Astex Guadecitabine Trials
2017-004603-52Phase 2Terminated
- Sponsor
- Astex Pharmaceuticals
- Start
- Jul 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of guadecitabine in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML), sponsored by Astex Pharmaceuticals. Primary endpoint: Safety as measured by adverse events. Started Jul 2018; status: terminated.
02
Drugs
guadecitabine
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on 2017-004603-52.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004603-52.